OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026

Key Takeaways

• REACH study shows 28‑38% RTI reduction at 12 months.
• Benefit observed across all age groups and comorbidities.
• Study includes 15,794 patients from China, Italy, Belgium.
• First multi‑country real‑world evidence for Broncho‑Vaxom®.
• Findings support non‑antibiotic prevention, aligning with EAACI Vision Zero.

Pulse Analysis

Recurrent respiratory tract infections (RTIs) remain a pervasive health challenge, driving missed workdays, school absences, and a surge in medical visits. Beyond personal suffering, they fuel antibiotic overprescription, aggravating the global antimicrobial‑resistance crisis. Preventive strategies that bolster innate immunity, such as bacterial‑lysate therapies, are gaining attention as sustainable alternatives to traditional drug regimens. In this context, OM‑85 (Broncho‑Vaxom®) offers a biologically grounded approach, training the immune system to fend off common pathogens without relying on antibiotics.

The REACH study, the first and largest multi‑country real‑world evidence (RWE) investigation of Broncho‑Vaxom®, analyzed secondary healthcare data from nearly 16,000 patients across China, Italy and Belgium. By comparing infection rates before and after treatment, the study documented a 28‑38% drop in RTI episodes at 12 months and up to 41% at 24 months, regardless of age or underlying conditions like asthma and COPD. Unlike controlled trials, REACH captures everyday clinical practice, reflecting true physician‑prescribed usage and real‑world patient adherence, thereby strengthening confidence in the therapy’s effectiveness across diverse health systems.

For the pharmaceutical market, these results could accelerate adoption of Broncho‑Vaxom® as a frontline preventive option, especially in regions seeking to curb antibiotic use and lower healthcare costs associated with frequent doctor visits. The data also dovetail with EAACI’s Vision Zero initiative, positioning OM Pharma as a key player in the shift toward non‑antibiotic, immune‑modulating solutions. As the second primary endpoint—matched untreated cohorts—awaits release later this year, stakeholders will watch for further evidence that could reshape guidelines for RTI management and expand the therapy’s market penetration worldwide.